Sept 24 (Reuters) – Chinese drugmaker InnoCare Pharma said on Thursday it entered into a research collaboration and license agreement with Eli Lilly that could be worth up to about $3.35 billion.
(Reporting by Aamir Shaik Khalid in Bengaluru; Editing by Subhranshu Sahu)
Comments